

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.6	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.2	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	Mild	Mild	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	Mild	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	Mild	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	37.2	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	37.2	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	37.3	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.2	None	None	Mild	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.2	None	None	Mild	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 14	MA	N/A			Mild			
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.5	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	Mild	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.3	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.6	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	37	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	37.1	None	None	None	None	None	None
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.9	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	37.1	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.8	None	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.5	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.6	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.4	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	36.8	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Pre-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	N/A	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	36.7	None	Mild	Mild	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	36.7	Mild	Mild	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	36.9	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	36.7	None	None	None	None	None	None

Appendix C1 (continued)
Solicited Systemic Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Fever (°C)	Feverishness	Fatigue	Myalgia	Arthralgia	Headache	Nausea
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	36.7	None	None	None	None	None	None
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	37.1	None	None	None	None	None	None

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
 Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
 See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

**APPENDIX C2:
Solicited Local Events**

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	Mild	0	1
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Moderate	0	75 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Moderate	0	78 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	Mild	0	36 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	Mild	0	26 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Moderate	0	65 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Moderate	0	76 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	23
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	Mild	0	35 (Mild)
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	20
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	15
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	Mild	None	1	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	Mild	None	1	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	Mild	None	3	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	Mild	None	3	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	Mild	None	3	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 10	MA		Mild		2	
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	1	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	1

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	10
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	Mild	None	None	0	8
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	3
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	Mild	0	2
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	3	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	Mild	None	2	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	Mild	None	2	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	3	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	Mild	None	2	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	Mild	None	65 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	65 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	40 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	40 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	None	50 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	Mild	None	25 (Mild)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	Mild	0	15
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	20
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	5

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	Mild	0	1
	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	Mild	Mild	Mild	2	3
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Moderate	None	Mild	0	50 (Moderate)
	25 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (56-70 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (56-70 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	3
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 5	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (56-70 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (56-70 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	Mild	0	2
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	Mild	Mild	5	30 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	Mild	Mild	60 (Moderate)	45 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	None	35 (Mild)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	Mild	40 (Mild)	40 (Mild)
	100 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	-	Mild	Mild	110 (Severe)	40 (Mild)
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	50 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	115 (Severe)	90 (Moderate)

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	Mild	80 (Moderate)	80 (Moderate)
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	Mild	None	60 (Moderate)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	Mild	None	60 (Moderate)	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	Not Done	Not Done	Not Done		
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	Mild	None	20	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	None	20	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	7
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	Mild	0	30 (Mild)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	Mild	0	20
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	Mild	0	30 (Mild)
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	None	Mild	0	1
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Mild	None	Mild	0	1
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	Mild	None	50 (Moderate)	50 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	01	Day 12	MA	-	Mild	.	105 (Severe)	105 (Severe)
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	Mild	Mild	10	60 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Moderate	Mild	Mild	75 (Moderate)	60 (Moderate)
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	Mild	Mild	105 (Severe)	25 (Mild)

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	Mild	Mild	None	60 (Moderate)	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	Not Done	Not Done	Not Done	.	.
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 1	MA	Moderate	Mild	None	2	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 2	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	01	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	01	Day 8	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Post-Dose	Clinic	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 1	MA	Moderate	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 2	MA	Mild	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 3	MA	Mild	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	250 mcg mRNA-1273 (18-55 years)	02	Day 4	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 5	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 6	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 7	MA	None	None	None	0	0
	250 mcg mRNA-1273 (18-55 years)	02	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	Mild	None	20	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	Mild	None	20	20
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	25 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	25 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Post-Dose	Clinic	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 1	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 2	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 3	MA	Mild	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 4	MA	None	None	None	0	0

Appendix C2 (continued)
Solicited Local Events

Subject ID	Vaccination Group	Dose Number	Post Dose Day	Assessment*	Pain	Erythema/redness	Induration/swelling	Erythema/redness measurement (mm)	Induration/swelling (mm)
(b) (6)	100 mcg mRNA-1273 (≥71 years)	01	Day 5	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 6	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 7	MA	None	None	None	0	0
	100 mcg mRNA-1273 (≥71 years)	01	Day 8	MA	None	None	None	0	0

*MA = Data reported by subject on the Memory Aid and reviewed by clinic staff and reported in Solicited Events eCRF.
Clinic = Data collected by clinic staff during physical exam or symptom assessment (treatment administration record, in-clinic assessment, etc.)
See Appendix D for listing of attributions for systemic events contributing toward halting criteria.

APPENDIX D:
Attribution for Systemic Solicited Events that Contribute to Halting Criteria

Subject ID	Vaccination Group	Systemic Reaction	Dose Number	Post-Dose Day	Severity	Attributed to Alternate Etiology?
(b) (6)	25 mcg mRNA-1273 (56-70 years)	Fever	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	1	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Headache	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Fever	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Fatigue	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Feverishness	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Myalgia	02	2	SEVERE	No
	250 mcg mRNA-1273 (18-55 years)	Nausea	02	2	SEVERE	No

**APPENDIX E:
Listing of Abnormal Clinical Laboratory Results**

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Alanine Aminotransferase (U/L)	9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Alkaline Phosphatase (U/L)	45	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Alkaline Phosphatase (U/L)	48	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Alkaline Phosphatase (U/L)	50	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Alkaline Phosphatase (U/L)	49	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Creatinine (mg/dL)	0.90	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Hemoglobin (g/dL)	14.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Hemoglobin (g/dL)	14.9	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Hemoglobin (g/dL)	14.0 (Mild)	NOT RELATED	Grade 1, due to phlebotomy procedure	NA- NOT APPLICABLE	No
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	PT (seconds)	11.8 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-14	PT (seconds)	10.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	PTT (seconds)	34 (Mild)	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Platelets (10 ³ /uL)	190	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Platelets (10 ³ /uL)	182	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	Platelets (10 ³ /uL)	204	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	Platelets (10 ³ /uL)	197	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	Platelets (10 ³ /uL)	212	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-22	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	MALE	30	-1	-15	WBC (10 ³ /uL)	4.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	1	1	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	8	8	WBC (10 ³ /uL)	4.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	29	29	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	30	36	36	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alanine Aminotransferase (U/L)	19	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alkaline Phosphatase (U/L)	82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	85	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Alkaline Phosphatase (U/L)	86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Alkaline Phosphatase (U/L)	81	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Aspartate Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Creatinine (mg/dL)	0.92	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Creatinine (mg/dL)	0.86	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Hemoglobin (g/dL)	15.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Hemoglobin (g/dL)	15.1 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Hemoglobin (g/dL)	14.7 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PT (seconds)	10.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PTT (seconds)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Platelets (10 ³ /uL)	332	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Platelets (10 ³ /uL)	334	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Platelets (10 ³ /uL)	358	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Platelets (10 ³ /uL)	343	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Platelets (10 ³ /uL)	366	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Serum Lipase (U/L)	24.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Serum Lipase (U/L)	16.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Serum Lipase (U/L)	22.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Serum Lipase (U/L)	27.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Serum Lipase (U/L)	28.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	WBC (10 ³ /uL)	5.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	7	WBC (10 ³ /uL)	6.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	28	WBC (10 ³ /uL)	6.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	35	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Alanine Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Alanine Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Alkaline Phosphatase (U/L)	54	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Alkaline Phosphatase (U/L)	62	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Creatinine (mg/dL)	0.88	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Creatinine (mg/dL)	0.82	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Creatinine (mg/dL)	0.78	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Serum Lipase (U/L)	23.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	Total Bilirubin (mg/dL)	0.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	-1	-4	WBC (10 ³ /uL)	7.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	1	1	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	8	8	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	29	28	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	28	36	35	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alanine Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Alanine Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Alanine Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Alanine Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Alkaline Phosphatase (U/L)	57	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Alkaline Phosphatase (U/L)	51	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Aspartate Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Creatinine (mg/dL)	0.97	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Hemoglobin (g/dL)	15.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Hemoglobin (g/dL)	15.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Hemoglobin (g/dL)	15.6 (Mild)	NOT RELATED	Due to phlebotomy (study procedure)	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Hemoglobin (g/dL)	15.2 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Hemoglobin (g/dL)	14.4 (Mild)	NOT RELATED	Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	PT (seconds)	10.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Platelets (10 ³ /uL)	163	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Platelets (10 ³ /uL)	185	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Platelets (10 ³ /uL)	195	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Platelets (10 ³ /uL)	170	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Platelets (10 ³ /uL)	162	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Serum Lipase (U/L)	12.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	Total Bilirubin (mg/dL)	1.5 (Mild)	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-2	Total Bilirubin (mg/dL)	1.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	Total Bilirubin (mg/dL)	1.4 (Mild)	NOT RELATED	Grade 1 Similar to baseline bilirubin	NC- DOSE NOT CHANGED	No

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	Total Bilirubin (mg/dL)	1.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	57	55	Total Bilirubin (mg/dL)	1.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	1	1	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	8	7	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	29	28	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	46	36	34	WBC (10 ³ /uL)	3.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alanine Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Alanine Aminotransferase (U/L)	41	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Alkaline Phosphatase (U/L)	59	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Alkaline Phosphatase (U/L)	56	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Alkaline Phosphatase (U/L)	58	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Alkaline Phosphatase (U/L)	55	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Aspartate Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Aspartate Aminotransferase (U/L)	25	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Aspartate Aminotransferase (U/L)	26	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Creatinine (mg/dL)	0.95	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Creatinine (mg/dL)	1.04	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Creatinine (mg/dL)	0.93	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Creatinine (mg/dL)	1.00	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Creatinine (mg/dL)	0.96	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Hemoglobin (g/dL)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Hemoglobin (g/dL)	14.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Hemoglobin (g/dL)	14.6 (Mild)	NOT RELATED	Due to study procedure - phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Hemoglobin (g/dL)	15.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Hemoglobin (g/dL)	14.3 (Mild)	NOT RELATED	study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	PTT (seconds)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Platelets (10 ³ /uL)	215	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Platelets (10 ³ /uL)	206	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Platelets (10 ³ /uL)	221	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Platelets (10 ³ /uL)	219	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Platelets (10 ³ /uL)	237	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Serum Lipase (U/L)	20.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Serum Lipase (U/L)	14.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Serum Lipase (U/L)	15.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Serum Lipase (U/L)	19.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Serum Lipase (U/L)	18.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	1	1	WBC (10 ³ /uL)	5.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	8	8	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	29	29	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	32	36	36	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Alanine Aminotransferase (U/L)	11	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Alanine Aminotransferase (U/L)	8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Alanine Aminotransferase (U/L)	7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Alanine Aminotransferase (U/L)	14	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Alkaline Phosphatase (U/L)	65	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Alkaline Phosphatase (U/L)	70	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Aspartate Aminotransferase (U/L)	12	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Aspartate Aminotransferase (U/L)	13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Aspartate Aminotransferase (U/L)	17	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Creatinine (mg/dL)	0.80	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Creatinine (mg/dL)	0.77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Creatinine (mg/dL)	0.79	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Creatinine (mg/dL)	0.73	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Hemoglobin (g/dL)	12.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Hemoglobin (g/dL)	12.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Hemoglobin (g/dL)	12.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Hemoglobin (g/dL)	12.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Hemoglobin (g/dL)	12.0 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	PT (seconds)	11.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	PTT (seconds)	27	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Platelets (10 ³ /uL)	222	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Platelets (10 ³ /uL)	226	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Platelets (10 ³ /uL)	252	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Platelets (10 ³ /uL)	227	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Platelets (10 ³ /uL)	231	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Serum Lipase (U/L)	54.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Serum Lipase (U/L)	53.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Serum Lipase (U/L)	78.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Serum Lipase (U/L)	70.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	57	56	Serum Lipase (U/L)	77.0	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	-1	-4	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	1	1	WBC (10 ³ /uL)	3.2 (Mild)	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	8	8	WBC (10 ³ /uL)	2.8 (Mild)	NOT RELATED	Grade 1 - similar to Grade 1 that was present prior to receipt of vaccine	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	29	29	WBC (10 ³ /uL)	4.3	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	36	35	WBC (10 ³ /uL)	3.0 (Mild)	NOT RELATED	Grade 1 Similar to her baseline	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	FEMALE	23	57	56	WBC (10 ³ /uL)	4.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Alanine Aminotransferase (U/L)	32	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Alanine Aminotransferase (U/L)	28	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Alanine Aminotransferase (U/L)	20	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Alanine Aminotransferase (U/L)	30	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Alanine Aminotransferase (U/L)	21	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Alkaline Phosphatase (U/L)	77	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Alkaline Phosphatase (U/L)	78	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Alkaline Phosphatase (U/L)	75	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Alkaline Phosphatase (U/L)	68	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Alkaline Phosphatase (U/L)	69	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Aspartate Aminotransferase (U/L)	18	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Aspartate Aminotransferase (U/L)	16	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Aspartate Aminotransferase (U/L)	22	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Aspartate Aminotransferase (U/L)	15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Creatinine (mg/dL)	1.08	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Creatinine (mg/dL)	1.16	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Creatinine (mg/dL)	1.15	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Creatinine (mg/dL)	1.13	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Creatinine (mg/dL)	1.02	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Hemoglobin (g/dL)	16.2	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Hemoglobin (g/dL)	16.7	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Hemoglobin (g/dL)	15.5 (Mild)	NOT RELATED	Due to study - phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Hemoglobin (g/dL)	15.3 (Mild)	NOT RELATED	Grade 1 Due to study procedures phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Hemoglobin (g/dL)	15.9 (Mild)	NOT RELATED	Grade 1 Due to study procedure phlebotomy	NC- DOSE NOT CHANGED	No
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	PT (seconds)	10.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	PTT (seconds)	30	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	Platelets (10 ³ /uL)	175	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	Platelets (10 ³ /uL)	168	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Platelets (10 ³ /uL)	174	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	Total Bilirubin (mg/dL)	0.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	-1	-4	WBC (10 ³ /uL)	5.7	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	1	1	WBC (10 ³ /uL)	4.8	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	8	8	WBC (10 ³ /uL)	4.9	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	29	29	WBC (10 ³ /uL)	5.6	N/A	N/A	N/A	N/A
	100 mcg mRNA-1273 (18-55 years)	MALE	21	36	36	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Alanine Aminotransferase (U/L)	10	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Serum Lipase (U/L)	48.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Serum Lipase (U/L)	59.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	Total Bilirubin (mg/dL)	0.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	Total Bilirubin (mg/dL)	0.4	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	Total Bilirubin (mg/dL)	0.3	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	-1	-21	WBC (10 ³ /uL)	5.2	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	1	1	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A

Appendix E (continued)
Listing of Abnormal Clinical Laboratory Results

Subject ID	Vaccination Group	Sex	Age (years)	Planned Study Day	Actual Study Day	Laboratory Parameter (Units)	Result (Severity)	Relationship to Vaccination	If Not Related, Alternative Etiology	Action Taken with Study Vaccination	Subject Discontinued Due to Result?
(b) (6)	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	8	7	WBC (10 ³ /uL)	5.0	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	29	28	WBC (10 ³ /uL)	5.1	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	FEMALE	24	36	35	WBC (10 ³ /uL)	5.5	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Alanine Aminotransferase (U/L)	33	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	1	1	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	8	7	Alanine Aminotransferase (U/L)	27	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	29	29	Alanine Aminotransferase (U/L)	35	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	36	35	Alanine Aminotransferase (U/L)	34	N/A	N/A	N/A	N/A
	250 mcg mRNA-1273 (18-55 years)	MALE	51	-1	-11	Alkaline Phosphatase (U/L)	74	N/A	N/A	N/A	N/A